Skip to Content

TRIOMEL 7 G/L NITROGEN 1140 KCAL/L EMULSION FOR INFUSION

Active substance(s): ALANINE / ARGININE / ASPARTIC ACID / GLUCOSE MONOHYDRATE / GLUTAMIC ACID / GLYCINE / HISTIDINE / ISOLEUCINE / LEUCINE / LYSINE ACETATE / METHIONINE / OLIVE OIL REFINED / PHENYLALANINE / PROLINE / REFINED SOYBEAN OIL / SERINE / THREONINE / TRYPTOPHAN / TYROSINE / VALINE

View full screen / Print PDF » Download PDF ⇩
Transcript
1. What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is and
what it is used for
TRIOMEL is an emulsion for infusion. It is presented in a bag with 3 chambers.
One chamber contains a glucose solution, the second one contains a lipid emulsion and the third one
contains an amino acid solution.
TRIOMEL is used to provide nutrition to adults and children greater than 2 years of age by a tube into a
vein when normal feeding by mouth is not suitable.
TRIOMEL must only be used under medical supervision.

2. What you need to know before TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion
for infusion is administered
TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion must not be used:






In premature neonates, infants, and children less than 2 years old.
If you are hypersensitive (allergic) to egg, soybean or peanut proteins or to any other ingredient.
If your body has problems using certain amino acids.
If you have an especially high level of fats in your blood.
If you have hyperglycemia (too much sugar in your blood).

In all cases, your doctor will base his/her decision on whether you should receive this medicine on
factors such as your age, weight, and medical condition, together with the results of any test performed.

1

BE-30-01-752

MARKETING
APPROVED

Date

Signature

1. What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is and what it is used for
2. What you need to know before TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is
administered
3. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion will be used
4. Possible side effects
5. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is stored
6. Contents of the pack and other information

Name

What is in this leaflet:

Country

• Keep this leaflet. You may need to read it again.
• If you have any further questions, ask your doctor or nurse.
• If you get any side effect, talk to your doctor or nurse. This includes any side effects not listed in
this leaflet. See section 4.

4th DRAFT

Read all of this leaflet carefully before you will be administered this medicine because it contains
important information for you.

ARTWORK APPROVAL

TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion

EUROPEAN LABELLING CENTRE

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT

RA
PROOFREAD + APPROVED

DATE 15 Apr 2014

b

Warnings and precautions
Talk to your doctor or nurse before TRIOMEL is administered to you.

To check the effectiveness and ongoing safety of the administration, your doctor will perform clinical and
laboratory tests while you are receiving this medicine. If you are given this medicine for several weeks,
your blood will be monitored on a regular basis.
Reduced ability of the body to remove the fats contained in this medicine may result in a “fat overload
syndrome” (See Section 4 – Possible Side Effects).
During the infusion if you notice pain, burning or swelling at the infusion site, or leakage of the infusion,
tell your doctor or nurse. The administration will be stopped immediately and restarted in another vein.
If your blood sugar gets too high, your doctor should adjust the rate of TRIOMEL delivery or give you
medication to control your blood sugar (insulin).
TRIOMEL may only be administered via a tube (catheter) into a large vein in your chest (central vein).

Children and adolescents
If your child is under 18 years old, special care will be taken to give him/her the correct dosage.
Increased precautions will also be taken because of the greater sensitivity of children to the risk of
infection. Vitamin and trace element supplementation is always required. Paediatric formulations must
be used.

Other medicines and TRIOMEL
Tell your doctor if you are taking or using, have recently taken or used or might take or use any other
medicines.
Simultaneous absorption of other medicinal products is not a contraindication, generally. If you take
other medicinal products, with or without medical prescription, you should inform your doctor in advance
to check compatibility.
2

BE-30-01-752

Date

Signature

Name

Country

Your doctor should be aware of:
• a severe kidney problem. You also must inform your doctor if you are on dialysis (artificial kidney)
or if you have another form of blood cleaning treatment
• a severe liver problem
• a blood clotting problem
• adrenal glands that are not working properly (adrenal insufficiency). The adrenal glands are
triangle-shaped glands located on top of your kidneys.
• heart failure
• lung disease
• a build up of water in your body (hyperhydration)
• not enough water in your body (dehydration)
• high blood sugar (diabetes mellitus) that you are not being treated for
• a heart attack or shock due to a sudden heart failure
• a severe metabolic acidosis (when the blood is too acidic)
• a generalised infection (septicaemia)
• coma.

DATE 15 Apr 2014

RA
PROOFREAD + APPROVED

The balance of water and salt in your body and metabolic disorders will be corrected before starting
the infusion. Your doctor will monitor your condition while you receive this medicine and may change
the dosage or give you additional nutrients, such as vitamins, electrolytes, and trace elements, if he/she
feels they are appropriate.

4th DRAFT

If you are severely malnourished such that you need to receive feedings by vein, your doctor should start
the treatment slowly. Also, your doctor should monitor you closely to prevent sudden changes in your
fluid, vitamin, electrolyte and mineral levels.

ARTWORK APPROVAL

Certain medications and illnesses can increase the risk of developing infection or sepsis (bacteria in the
blood). There is a particular risk of infection or sepsis when a tube (intravenous catheter) is placed in
your vein. Your doctor will carefully watch you for any signs of infection. Patients who require parenteral
nutrition (giving nutrition through a tube in your vein) may be more likely to develop infections from their
medical conditions. Using aseptic (“germ-free”) techniques when placing and caring for the catheter and
when making the nutritional formula (TPN) can reduce the risk of infection.

EUROPEAN LABELLING CENTRE

The infusion must be stopped immediately if any abnormal signs or symptoms of an allergic reaction
(such as sweating, fever, chills, headache, skin rashes, or difficulty breathing) develop. This medicinal
product contains soybean oil and egg phosphatide. Soybean and egg proteins may cause hypersensitivity
reactions. Cross-allergic reactions between soybean and peanut proteins have been observed.

MARKETING
APPROVED

If you are given total parenteral nutrition (TPN) solutions too fast this may result in injury or death.

TRIOMEL must not be administered simultaneously with blood through the same infusion tubing.

TRIOMEL should be at room temperature before use.
TRIOMEL is for single use only.
The infusion of 1 bag usually lasts between 12 and 24 hours.

Dosage – Adults
Your doctor will specify a flow rate corresponding to your needs and clinical condition.
The prescription may be continued for as long as it is needed, depending upon your clinical condition.

Dosage – Children greater than two years of age and adolescents
The doctor will decide the dose and for how long the medication will be given. This will depend on age,
weight, height, medical condition and the ability of the body to break down and use the ingredients in
TRIOMEL.

If you have been administered more TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion
for infusion than you should
If the dose given is too high or the infusion is too fast, the amino acid content may make your blood
too acidic, and signs of hypervolaemia (increase of circulating blood volume) may occur. The glucose
levels in your blood and urine may increase, hyperosmolar syndrome (excessive blood viscosity) may
develop, and the lipid content may increase the level of triglycerides in your blood. Receiving a volume
of TRIOMEL that is too large may cause nausea, vomiting, chills and electrolyte disturbances. In such
situations, the infusion must be stopped immediately.
In some severe cases, your doctor may have to give you temporary renal dialysis to help your kidneys
eliminate the excess product.
To prevent these events occurring, your doctor will regularly monitor your condition and test your blood
parameters.
If you have any further questions on the use of this product, ask your doctor.

3

BE-30-01-752

Date

It is an emulsion for infusion, to be administered via a tube (catheter) into a vein in your chest.

Signature

TRIOMEL should only be given in adults and children greater than 2 years of age.

Name

Dosage

Country

3. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion will be used

4th DRAFT

TRIOMEL may be considered during pregnancy and breastfeeding, if necessary.

ARTWORK APPROVAL

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask
your doctor for advice before taking this medicine.

EUROPEAN LABELLING CENTRE

Pregnancy, breast-feeding and fertility

RA
PROOFREAD + APPROVED

DATE 15 Apr 2014

The lipids contained in this emulsion may interfere with the results of certain laboratory tests if the
blood sample is taken before the lipids have been eliminated from your bloodstream (these are generally
eliminated after a period of 5 to 6 hours without receiving lipids).

MARKETING
APPROVED

The olive and soybean oils present in TRIOMEL contain vitamin K. This does not normally affect blood
thinning medicines (anticoagulants) like coumarin. However, if you take anticoagulant medicines you
should tell your doctor.

4. Possible side effects

Reporting of side effects
If you get any side effect, talk to your doctor or nurse. This includes any possible side effect not listed in
this leaflet. You can also report side effects directly (see details below). By reporting side effects you can
help provide more information on the safety of this medicine.
Malta
ADR Reporting
The Medicines Authority
Post-Licensing Directorate
203 Level 3, Rue D’Argens
GŻR-1368 Gżira
Website: www.medicinesauthority.gov.mt
e-mail: postlicensing.medicinesauthority@gov.mt

4

BE-30-01-752

Date

Signature

Name

Country

The following side effects have been reported with similar parenteral nutrition products:
Frequency – Very rare: may affect up to 1 in 10000 people
• Reduced ability to remove the lipids (fat overload syndrome) associated with sudden and abrupt
worsening of the patient’s medical condition. The following signs of fat overload syndrome are
usually reversible when the lipid emulsion infusion is stopped:
– Fever
– Reduction in red blood cells which can make the skin pale and cause weakness or
breathlessness (anaemia)
– Low white blood cell count, which can increase the risk of infection (leukopenia)
– Low platelet count which can increase the risk of bruising and/or bleeding (thrombocytopenia)
– Coagulation disorders which effect the ability of the blood to clot
– High levels of fats in the blood (hyperlipidaemia)
– Liver fatty infiltration (hepatomegaly)
– Worsening liver function
– Central nervous system manifestations (e.g. Coma).
Frequency – Not known: frequency cannot be estimated from the available data
• Allergic reactions
• Abnormal blood test results for liver function
• Problems with the elimination of bile (cholestasis)
• Increase in the size of the liver (hepatomegaly)
• Icterus (jaundice)
• Decrease in the number of platelets (thrombocytopenia)
• Increased nitrogen levels in the blood (azotemia) Elevated liver enzymes

4th DRAFT

The following side effects have been reported with TRIOMEL:
Frequency – Common: may affect up to 1 in 10 people
• Fast heart rate (tachycardia)
• Loss of appetite (anorexia)
• Increased level of fat in the blood (hypertriglyceridemia)
• Abdominal pain
• Diarrhoea
• Nausea
• Increased blood pressure (hypertension)
Frequency – Not known: frequency cannot be estimated from the available data
• Leakage of the infusion to the surrounding tissue (extravasation) which may result at infusion site
level in pain, irritation, swelling/oedema, redness (erythema)/warmth, death of the tissue cells
(skin necrosis) or blisters

ARTWORK APPROVAL

If any abnormal signs or symptoms of an allergic reaction develop, such as sweating, fever, chills,
headache, skin rashes, or breathing difficulties, the infusion should be stopped immediately.

EUROPEAN LABELLING CENTRE

The tests your doctor will perform while you are taking the medicine should minimise the risk of side
effects.

RA
PROOFREAD + APPROVED

DATE 15 Apr 2014

If you notice any changes in the way you feel during or after the treatment, tell your doctor or nurse right
away.

MARKETING
APPROVED

Like all medicines, this medicine can cause side effects, although not everybody gets them.

6. Contents of the pack and other information
What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion contains
The active substances for each bag of the reconstituted emulsion are 11.1% (corresponding to
11.1 g/100 ml) L-amino acid solution (alanine, arginine, glycine, histidine, isoleucine, leucine, lysine
(as lysine acetate), methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine,
aspartic acid, glutamic acid), 20% (corresponding to 20 g/100 ml) lipid emulsion (refined olive oil and
refined soybean oil), and 35% (corresponding to 35 g/100 ml) glucose solution (as glucose monohydrate).
The other ingredients are:
Lipid emulsion
compartment

Amino acid solution
compartment

Glucose solution
compartment

Purified egg phosphatide,
glycerol, sodium oleate, sodium
hydroxide (for pH adjustment),
water for injection

Glacial acetic acid
(for pH adjustment), water for
injection

Hydrochloric acid
(for pH adjustment), water for
injection

What TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion looks like and
contents of the pack
TRIOMEL is an emulsion for infusion packaged in a 3-compartment bag. One compartment contains
a lipid emulsion, another compartment an amino acid solution and the third compartment a glucose
solution. These compartments are separated by nonpermanent seals. Before administration, the content
of the compartments need to be mixed by rolling the bag onto itself, starting at the top of the bag until
the peal seal is open.

5

BE-30-01-752

DATE 15 Apr 2014

MARKETING
APPROVED

Date

Signature

Store in the overpouch.
Do not throw away medicines via wastewater or household waste. Ask your pharmacist how to throw
away medicines you no longer use. These measures will help protect the environment.

Name

Do not freeze.

Country

Do not use this medicine after the expiry date that is stated on the container and the outer packaging
(MM/YYYY). The expiry date refers to the last day of that month.

RA
PROOFREAD + APPROVED

Keep this medicine out of the sight and reach of children.

4th DRAFT

5. How TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion is stored

ARTWORK APPROVAL

United Kingdom:
Via the Yellow Card Scheme at:
www.mhra.gov.uk/yellowcard

EUROPEAN LABELLING CENTRE

Republic of Ireland:
FREEPOST,
Pharmacovigilance Section,
Irish Medicines Board,
Kevin O’Malley House,
Earlsfort Centre,
Earlsfort Terrace,
Dublin 2,
Ireland.
Tel: +353 1 6764971,
Fax: +353 1 6762517,
Website: www.imb.ie
e-mail: imbpharmacovigilance@imb.ie

Appearance prior to reconstitution:

Manufacturer
BAXTER S.A.
BOULEVARD RENE BRANQUART, 80
7860 LESSINES
BELGIUM
This medicinal product is authorised in the Member States of the EEA under the following names:
France, Portugal, Estonia, Poland, Lithuania, Bulgaria,
Romania, Latvia, Belgium, Spain, The Netherlands,
Luxemburg, Slovenia, Italy, Greece:

OLIMEL N7

In some countries it is registered under a different trade name, as described below:
Austria:
Germany:
Denmark, Iceland, Sweden, Norway, Finland:
The United Kingdom, Ireland, Malta:

ZentroOLIMEL 4,4 %
Olimel 4,4%
Olimel N7
Triomel 7g/l nitrogen 1140 kcal/l

This leaflet was last revised in 04/2014.

For information about TRIOMEL or to request this
leaflet in formats such as audio or large print
please contact the Marketing Authorisation Holder:
Tel: +44 (0)1635 206345
Baxter, Triomel and Oxydetect are trademarks of Baxter international Inc.

6

BE-30-01-752

Date

Baxter Healthcare Limited
Caxton Way, Thetford,
Norfolk, IP24 3SE
United Kingdom

Signature

Marketing Authorisation Holder

Name

Not all pack sizes may be marketed.

Country

1000 ml bag: 1 carton with 6 bags
1500 ml bag: 1 carton with 4 bags
2000 ml bag: 1 carton with 4 bags
1 bag of 1000 ml, 1500 ml and 2000 ml

4th DRAFT

Pack sizes

ARTWORK APPROVAL

To prevent contact with oxygen contained in the air, the bag is packaged in an oxygen barrier overpouch
with an oxygen absorber sachet that may include an oxygen indicator (OXYDETECT).

EUROPEAN LABELLING CENTRE

The 3-compartment bag is a multilayer plastic bag. The inner (contact) layer of the bag material is
designed to be compatible with the constituents and authorised additives.

RA
PROOFREAD + APPROVED

DATE 15 Apr 2014

Appearance after reconstitution: homogeneous milk-like emulsion.

MARKETING
APPROVED

• The amino acid and glucose solutions are clear, colourless, or slightly yellow.
• The lipid emulsion is homogenous with a milky appearance.

2000 ml

400 ml

600 ml

800 ml

11.1% Amino acid solution
(corresponding to 11.1 g/100 ml)

400 ml

600 ml

800 ml

20% Lipid emulsion
(corresponding to 20 g/100 ml)

200 ml

300 ml

400 ml

Composition of the reconstituted emulsion after mixing the contents of the 3 compartments:
Active substances

1000 ml

1500 ml

2000 ml

Refined olive oil + refined soybean oila

40.00 g

60.00 g

80.00 g

Alanine

6.41 g

9.61 g

12.82 g

Arginine

4.34 g

6.51 g

8.68 g

Aspartic acid

1.28 g

1.92 g

2.56 g

Glutamic acid

2.21 g

3.32 g

4.42 g

Glycine

3.07 g

4.60 g

6.14 g

Histidine

2.64 g

3.97 g

5.29 g

Isoleucine

2.21 g

3.32 g

4.42 g

Leucine

3.07 g

4.60 g

6.14 g

Lysine
(equivalent to lysine acetate)

3.48 g
(4.88 g)

5.23 g
(7.31 g)

6.97 g
(9.75 g)

Methionine

2.21 g

3.32 g

4.42 g

Phenylalanine

3.07 g

4.60 g

6.14 g

Proline

2.64 g

3.97 g

5.29 g

Serine

1.75 g

2.62 g

3.50 g

Threonine

2.21 g

3.32 g

4.42 g

Tryptophan

0.74 g

1.10 g

1.47 g

Tyrosine

0.11 g

0.17 g

0.22 g

Valine

2.83 g

4.25 g

5.66 g

140.00 g
(154.00 g)

210.00 g
(231.00 g)

280.00 g
(308.00 g)

Glucose anhydrous
(equivalent to glucose monohydrate)

a: Mixture of refined olive oil (approximately 80%) and refined soybean oil (approximately 20%)
corresponding to a ratio essential fatty acids/total fatty acids of 20%.

7

BE-30-01-752

MARKETING
APPROVED

Date

1500 ml

35% Glucose solution
(corresponding to 35 g/100 ml)

Signature

Contents per bag
1000 ml

Name

Each bag contains a glucose solution, a lipid emulsion and an amino acid solution.

Country

TRIOMEL is presented in the form of a 3-compartment bag.

ARTWORK APPROVAL

A. QUALITATIVE AND QUANTITATIVE COMPOSITION

EUROPEAN LABELLING CENTRE

Pharmacotherapeutic group: Solutions for parenteral nutrition/combinations
ATC code: B05 BA10.

4th DRAFT

TRIOMEL 7 g/l nitrogen 1140 kcal/l, emulsion for infusion

RA
PROOFREAD + APPROVED

DATE 15 Apr 2014

The following information is intended for medical
or healthcare professionals only:

60 g

2000 ml
80 g

Amino acids

44.3 g

66.4 g

88.6 g

Nitrogen

7.0 g

10.5 g

14.0 g

Glucose

140.0 g

210.0 g

280.0 g

Energy:
Total calories approx.

1140 kcal

1710 kcal

2270 kcal

Non-protein calories

960 kcal

1440 kcal

1920 kcal

Glucose calories

560 kcal

840 kcal

1120 kcal

Lipid caloriesa

400 kcal

600 kcal

800 kcal

Non-protein calories/nitrogen ratio

137 kcal/g

137 kcal/g

137 kcal/g

Glucose/lipid calories ratio

58/42

58/42

58/42

Lipid/total calories

35%

35%

35%

Phosphateb

3.0 mmol

4.5 mmol

6.0 mmol

Acetate

31 mmol

46 mmol

62 mmol

6.4

6.4

6.4

1220 mosm/l

1220 mosm/l

1220 mosm/l

Electrolytes:

pH
Osmolarity

a: Includes calories from purified egg phosphatide
b: Includes phosphate provided by the lipid emulsion

B. POSOLOGY AND METHOD OF ADMINISTRATION
Posology
TRIOMEL is not recommended for use in children less than 2 years of age due to inadequate composition
and volume (see sections 4.4; 5.1 and 5.2 of the SmPC).
In adults
The dosage depends on the patient’s energy expenditure, clinical status, body weight, and the ability
to metabolise the constituents of TRIOMEL, as well as additional energy or proteins provided
orally/enterally; therefore, the bag size should be chosen accordingly.
The average daily requirements are:
– 0.16 to 0.35 g nitrogen/kg body weight (1 to 2 g of amino acids/kg), depending on the patient’s
nutritional status and degree of catabolic stress,
– 20 to 40 kcal/kg,
– 20 to 40 ml fluid/kg, or 1 to 1.5 ml per expended kcal.
For TRIOMEL, the maximal daily dose is defined by total caloric intake, 40 kcal/kg provided in a volume
of 35 ml/kg, corresponding to 1.5 g/kg amino acids, 4.9 g/kg glucose, and 1.4 g/kg lipids. For a 70 kg
patient, this would be equivalent to 2450 ml TRIOMEL per day, resulting in an intake of 108 g amino
acids, 343 g glucose, and 98 g lipids (i.e., 2352 non-protein kcal and 2793 total kcal).
Normally, the flow rate must be increased gradually during the first hour and then be adjusted to take
into account the dose being administered, the daily volume intake, and the duration of the infusion.
For TRIOMEL, the maximal infusion rate is 1.7 ml/kg/hour, corresponding to 0.08 g/kg/hour amino acids,
0.24 g/kg/hour glucose, and 0.07 g/kg/hour lipids.

8

BE-30-01-752

Date

1500 ml

40 g

ARTWORK APPROVAL

1000 ml
Lipids

EUROPEAN LABELLING CENTRE

Nutritional intakes of reconstituted emulsion for each of the bag sizes:

Signature

Hydrochloric acid
(for pH adjustment), water for
injection

Name

Glacial acetic acid
(for pH adjustment), water for
injection

Country

Purified egg phosphatide,
glycerol, sodium oleate, sodium
hydroxide (for pH adjustment),
water for injection

MARKETING
APPROVED

Glucose solution
compartment

RA
PROOFREAD + APPROVED

Amino acid solution
compartment

4th DRAFT

Lipid emulsion compartment

DATE 15 Apr 2014

The excipients are:

Fluids (ml/kg/d)
Amino acids (g/kg/d)

67

50 – 80

45

2.9

1–2

2.0

Glucose (g/kg/d)

12 – 14 (up to 18)

9.3

3 – 10 (up to 14)

6.4

Lipids (g/kg/d)

0.5 – 3

2.7

0.5 – 2 (up to 3)

1.8

Total energy (kcal/kg/d)

60 – 90

76

30 – 75

52

0.20

0.15

0.12

0.12

Glucose (g/kg/h)

1.2

0.46

1.2

0.38

Lipids (g/kg/h)

0.13

0.13

0.13

0.11

Maximum Hourly Rate
TRIOMEL (ml/kg/h)
Amino acids (g/kg/h)

3.3

2.7

a: Recommended values from 2005 ESPGHAN/ESPEN Guidelines
Normally, the flow rate must be increased gradually during the first hour and then be adjusted to take
into account the dose being administered, the daily volume intake, and the duration of the infusion.
In general, it is recommended to start the infusion for small children with low daily dose and gradually
increase it up to the maximal dosage (see above).

Method and duration of administration
For single use only.
It is recommended that, after opening the bag, the contents are used immediately and not stored for
subsequent infusion.
After reconstitution, the mixture is homogenous with a milky appearance.
For instructions for preparation and handling of the emulsion for infusion, see section 6.6 of the SmPC.
Due to its high osmolarity, TRIOMEL can only be administered through a central vein.
The recommended duration of infusion for a parenteral nutrition bag is between 12 and 24 hours.
Treatment with parenteral nutrition may be continued for as long as required by the patient’s clinical
conditions.

9

BE-30-01-752

Date

60 – 120
1 – 2 (up to 3)

Maximum Daily Dose

Signature

TRIOMEL
Max Vol

Name

Recommendeda

Recommendeda

Country

12 to 18 years

TRIOMEL
Max Vol

4th DRAFT

2 to 11 years
Constituent

ARTWORK APPROVAL

For TRIOMEL in the 2 to 11 year age group, the limiting factors are phosphate concentration for daily
dose (0.2 mmol/kg/day)a and lipid concentration for hourly rate. In the 12 to 18 year age group, amino
acid concentration is the limiting factor for both daily dose and hourly rate. The resulting intakes are
displayed below:

EUROPEAN LABELLING CENTRE

In addition, daily fluid, nitrogen, and energy requirements continuously decrease with age. Two groups,
ages 2 to 11 years and 12 to 18 years, are considered.

RA
PROOFREAD + APPROVED

DATE 15 Apr 2014

The dosage depends on the patient’s energy expenditure, clinical status, body weight, and the ability
to metabolise constituents of TRIOMEL, as well as additional energy or proteins given orally/enterally;
therefore, the bag size should be chosen accordingly.

MARKETING
APPROVED

In children greater than 2 years of age
There have been no studies performed in the paediatric population.

Remove the protective overpouch.
Discard the oxygen absorber/oxygen indicator sachet.
Confirm the integrity of the bag and of the nonpermanent seals. Use only if the bag is not damaged; if
the nonpermanent seals are intact (i.e., no mixture of the contents of the 3 compartments); if the amino
acid solution and the glucose solution are clear, colourless, or slightly yellow, and practically free of
visible particles; and if the lipid emulsion is a homogeneous liquid with a milky appearance.

Mixing the solutions and the emulsion
Ensure that the product is at room temperature when breaking the nonpermanent seals.
Manually roll the bag onto itself, starting at the top of the bag (hanger end). The nonpermanent seals
will disappear from the side near the inlets. Continue to roll the bag until the seals are open along
approximately half of their length.
Mix by inverting the bag at least 3 times.
After reconstitution, the mixture is a homogeneous emulsion with a milky appearance.

Additions
The capacity of the bag is sufficient to enable additions such as vitamins, electrolytes, and trace
elements.
Any additions (including vitamins) may be made into the reconstituted mixture (after the nonpermanent
seals have been opened and after the contents of the 3 compartments have been mixed).
Vitamins may also be added into the glucose compartment before the mixture is reconstituted (before
opening the nonpermanent seals and before mixing the 3 compartments).
When making additions to formulations containing electrolytes, the amount of electrolytes already
present in the bag should be taken into account.

10

BE-30-01-752

Date

To open

Signature

An overview of the preparation steps for the administration of TRIOMEL are provided in Figure 1.

Name

Check the colour of the oxygen indicator, if present, before opening the overpouch. Compare it to the
reference colour printed next to the OK symbol and depicted in the printed area of the indicator label.
Do not use the product if the colour of the oxygen indicator does not correspond to the reference colour
printed next to OK symbol.

Country

D. SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

DATE 15 Apr 2014

RA
PROOFREAD + APPROVED

Do not administer before, simultaneously with, or after blood through the same equipment because of
the risk of pseudoagglutination.

4th DRAFT

Check compatibility with solutions administered simultaneously through the same administration set,
catheter, or cannula.

ARTWORK APPROVAL

Incompatibilities may be produced, for example, by excessive acidity (low pH) or inappropriate content of
divalent cations (Ca2+ and Mg2+), which may destabilize the lipid emulsion.
As with any parenteral nutrition admixture, calcium and phosphate ratios must be considered. Excess
addition of calcium and phosphate, especially in the form of mineral salts, may result in the formation of
calcium phosphate precipitates.

EUROPEAN LABELLING CENTRE

Do not add other medicinal products or substances to any components of the bag or to the reconstituted
emulsion without first confirming their compatibility and the stability of the resulting preparation (in
particular, the stability of the lipid emulsion).

MARKETING
APPROVED

C. INCOMPATIBILITIES

Additions must be performed by qualified personnel under aseptic conditions.
TRIOMEL may be supplemented with electrolytes according to the table below:

5.6 mmol
5.0 (3.5a) mmol

Inorganic Phosphate

0 mmol

8.0 mmol

8.0 mmol

mmolb

22 mmol

25 mmolb

Organic Phosphate

3

a: Value corresponding to the addition of inorganic phosphate.
b: Including phosphate provided by the lipid emulsion.
Trace elements and vitamins:
Stability has been demonstrated with commercially-available preparations of vitamins and trace
elements (containing up to 1 mg of iron).
Compatibility for other additives is available upon request.
When making additions, the final osmolarity of the mixture must be measured before administration via
a peripheral vein.
To perform an addition:
– Aseptic conditions must be observed.
– Prepare the injection site of the bag.
– Puncture the injection site and inject the additives using an injection needle or a reconstitution
device.
– Mix content of the bag and the additives.

Preparation of the infusion
Aseptic conditions must be observed.
Suspend the bag.
Remove the plastic protector from the administration outlet.
Firmly insert the spike of the infusion set into the administration outlet.
Figure 1: Preparation steps for the administration of TRIOMEL
1.

2.

Tear from the top to open the
overpouch.

3.

Peel the front of the overpouch
to reveal the TRIOMEL bag.
Discard the overpouch and
oxygen absorber sachet.
5.

4.

Lift the hanger area to remove
solution from the upper bag. Roll
the upper part of the bag firmly
until peal seals are fully open
(approximately half way).

Place the bag flat on a
horizontal and clean surface
with the handle in front of you.
6.

Mix by turning the bag
upside-down at least 3 times.

11

Hang the bag. Twist off
the protector from the
administration outlet. Firmly
plug the spike connector.
BE-30-01-752

Date

5.6 mmol
5.0 (3.5a) mmol

Signature

0 mmol
0 mmol

Name

Magnesium
Calcium

Country

150 mmol
150 mmol

RA
PROOFREAD + APPROVED

150 mmol
150 mmol

4th DRAFT

0 mmol
0 mmol

ARTWORK APPROVAL

Sodium
Potassium

DATE 15 Apr 2014

Maximal total level

EUROPEAN LABELLING CENTRE

Maximal further
addition

MARKETING
APPROVED

Per 1000 ml
Included level

Catheter site should be monitored regularly to identify signs of extravasation.
If extravasation occurs, the administration should be stopped immediately, keeping the inserted catheter
or cannula in place for immediate management of the patient. If possible, aspiration should be performed
through the inserted catheter/cannula, in order to reduce the amount of fluid present in the tissues
before removing the catheter/cannula.
Depending on the extravasated product (including the product(s) being mixed with TRIOMEL, if
applicable) and the stage/extend of any injury, appropriate specific measures should be taken. Options
for management may include non-pharmacologic, pharmacologic and/or surgical intervention. In case of
large extravasation, plastic surgeon advice should be sought within the first 72 hours.
The extravasation site should be monitored at least every 4 hours during the 24 first hours, then once
daily.
The infusion should not be restarted in the same central vein.

12

BE-30-01-752

MARKETING
APPROVED

Date

Extravasation

Signature

Any unused product or waste material and all necessary devices must be discarded.

Name

Do not connect bags in series in order to avoid the possibility of air embolism due to gas contained in
the primary bag.

Country

After opening the bag, the contents must be used immediately. The opened bag must never be stored for
a subsequent infusion. Do not reconnect any partially used-bag.

RA
PROOFREAD + APPROVED

DATE 15 Apr 2014

Ensure that the final emulsion for infusion does not show any evidence of phase separation.

ARTWORK APPROVAL

Only administer the product after the nonpermanent seals between the 3 compartments have been
broken and the contents of the 3 compartments have been mixed.

EUROPEAN LABELLING CENTRE

For single use only.

4th DRAFT

Administration

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide